Does the media refer more to IRWD or ABBV?

In the previous week, AbbVie had 47 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 55 mentions for AbbVie and 8 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.10 beat Ironwood Pharmaceuticals' score of 0.57 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 39 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer ZBIO or IRWD?

In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for Ironwood Pharmaceuticals and 6 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.68 beat Ironwood Pharmaceuticals' score of 0.57 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRWD or INVA?

In the previous week, Ironwood Pharmaceuticals had 5 more articles in the media than Innoviva. MarketBeat recorded 8 mentions for Ironwood Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.37 beat Ironwood Pharmaceuticals' score of 0.57 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRWD or NVAX?

In the previous week, Novavax had 8 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 16 mentions for Novavax and 8 mentions for Ironwood Pharmaceuticals. Novavax's average media sentiment score of 0.91 beat Ironwood Pharmaceuticals' score of 0.57 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Ironwood Pharmaceuticals (IRWD) Competitors

$4.04 +0.06 (+1.38%)

As of 01:29 PM Eastern

Compare

IRWD vs. ABBV, BCRX, ZBIO, INVA, and NVAX

Should you buy Ironwood Pharmaceuticals stock or one of its competitors? MarketBeat compares Ironwood Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ironwood Pharmaceuticals include AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "medical" sector.

How does Ironwood Pharmaceuticals compare to AbbVie?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to AbbVie's net margin of 5.79%. Ironwood Pharmaceuticals' return on equity of -39.65% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
AbbVie	5.79%	-576.45%	13.39%

In the previous week, AbbVie had 47 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 55 mentions for AbbVie and 8 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.10 beat Ironwood Pharmaceuticals' score of 0.57 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	39 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, suggesting a potential upside of 54.48%. AbbVie has a consensus price target of $267.67, suggesting a potential upside of 8.57%. Given Ironwood Pharmaceuticals' higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.71
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84

70.2% of AbbVie shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.22	$24.02M	$0.60	6.73
AbbVie	$62.82B	6.93	$4.23B	$2.03	121.45

Summary

AbbVie beats Ironwood Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ironwood Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, suggesting a potential upside of 54.48%. BioCryst Pharmaceuticals has a consensus target price of $20.80, suggesting a potential upside of 120.46%. Given BioCryst Pharmaceuticals' higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.71
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ironwood Pharmaceuticals has a net margin of 28.26% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Ironwood Pharmaceuticals' return on equity of -39.65% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 8 mentions for Ironwood Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.15 beat Ironwood Pharmaceuticals' score of 0.57 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has higher revenue and earnings than Ironwood Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.22	$24.02M	$0.60	6.73
BioCryst Pharmaceuticals	$874.84M	2.74	$263.86M	-$1.78	N/A

Summary

BioCryst Pharmaceuticals beats Ironwood Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Zenas BioPharma presently has a consensus price target of $44.29, suggesting a potential upside of 55.26%. Ironwood Pharmaceuticals has a consensus price target of $6.23, suggesting a potential upside of 54.48%. Given Zenas BioPharma's higher probable upside, equities research analysts clearly believe Zenas BioPharma is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Ironwood Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.71

Zenas BioPharma has a beta of -0.96, suggesting that its stock price is 196% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

In the previous week, Ironwood Pharmaceuticals had 2 more articles in the media than Zenas BioPharma. MarketBeat recorded 8 mentions for Ironwood Pharmaceuticals and 6 mentions for Zenas BioPharma. Zenas BioPharma's average media sentiment score of 0.68 beat Ironwood Pharmaceuticals' score of 0.57 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Zenas BioPharma's net margin of 0.00%. Ironwood Pharmaceuticals' return on equity of -39.65% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Ironwood Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.47	N/A
Ironwood Pharmaceuticals	$296.15M	2.22	$24.02M	$0.60	6.73

Summary

Ironwood Pharmaceuticals beats Zenas BioPharma on 11 of the 14 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Innoviva?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, indicating a potential upside of 54.48%. Innoviva has a consensus price target of $36.20, indicating a potential upside of 65.09%. Given Innoviva's higher probable upside, analysts plainly believe Innoviva is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.71
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Ironwood Pharmaceuticals had 5 more articles in the media than Innoviva. MarketBeat recorded 8 mentions for Ironwood Pharmaceuticals and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.37 beat Ironwood Pharmaceuticals' score of 0.57 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Innoviva shares are owned by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ironwood Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Innoviva has higher revenue and earnings than Ironwood Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.22	$24.02M	$0.60	6.73
Innoviva	$411.33M	3.93	$271.17M	$6.01	3.65

Innoviva has a net margin of 119.89% compared to Ironwood Pharmaceuticals' net margin of 28.26%. Innoviva's return on equity of 33.33% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
Innoviva	119.89%	33.33%	22.67%

Summary

Innoviva beats Ironwood Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Novavax?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
Novavax	-14.73%	-14.82%	1.23%

Ironwood Pharmaceuticals presently has a consensus price target of $6.23, indicating a potential upside of 54.48%. Novavax has a consensus price target of $13.00, indicating a potential upside of 55.71%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.71
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

53.0% of Novavax shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Novavax has higher revenue and earnings than Ironwood Pharmaceuticals. Novavax is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.22	$24.02M	$0.60	6.73
Novavax	$1.12B	1.22	$440.30M	-$0.58	N/A

In the previous week, Novavax had 8 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 16 mentions for Novavax and 8 mentions for Ironwood Pharmaceuticals. Novavax's average media sentiment score of 0.91 beat Ironwood Pharmaceuticals' score of 0.57 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Novavax has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Summary

Novavax beats Ironwood Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRWD vs. The Competition

Export

Metric	Ironwood Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$657.95M	$2.99B	$6.78B	$12.59B
Dividend Yield	N/A	2.08%	2.68%	8.43%
P/E Ratio	6.73	19.06	27.11	24.33
Price / Sales	2.22	350.47	525.10	92.04
Price / Cash	16.36	56.83	48.59	59.39
Price / Book	-2.51	4.23	10.82	6.30
Net Income	$24.02M	$65.13M	$3.59B	$331.45M
7 Day Performance	-15.41%	-2.82%	-1.53%	-0.08%
1 Month Performance	9.35%	1.79%	2.75%	-0.96%
1 Year Performance	487.34%	23.04%	28.40%	19.89%

Ironwood Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRWD Ironwood Pharmaceuticals	2.7479 of 5 stars	$4.04 +1.4%	$6.23 +54.5%	+439.2%	$657.95M	$296.15M	6.73	220	News Coverage
ABBV AbbVie	4.7777 of 5 stars	$254.77 -2.4%	$256.67 +0.7%	+27.8%	$461.26B	$61.16B	125.50	57,000	Trending News Analyst Forecast Options Volume
BCRX BioCryst Pharmaceuticals	3.1883 of 5 stars	$10.17 +3.4%	$21.67 +113.0%	+8.7%	$2.50B	$874.84M	N/A	530	Positive News Analyst Forecast
ZBIO Zenas BioPharma	3.5162 of 5 stars	$26.45 -2.9%	$44.29 +67.4%	+124.5%	$1.72B	$10M	N/A	N/A
INVA Innoviva	3.7526 of 5 stars	$21.82 -2.2%	$36.20 +65.9%	+11.0%	$1.65B	$411.33M	3.63	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRWD) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BCRX, ZBIO, INVA, and NVAX

How does Ironwood Pharmaceuticals compare to AbbVie?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Ironwood Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, BCRX, ZBIO, INVA, and NVAX

How does Ironwood Pharmaceuticals compare to AbbVie?

Is IRWD or ABBV more profitable?

Does the media refer more to IRWD or ABBV?

Which has more risk and volatility, IRWD or ABBV?

Do analysts recommend IRWD or ABBV?

Do insiders and institutionals hold more shares of IRWD or ABBV?

Which has higher earnings & valuation, IRWD or ABBV?

Summary

How does Ironwood Pharmaceuticals compare to BioCryst Pharmaceuticals?

Do institutionals and insiders have more ownership in IRWD or BCRX?

Which has more risk & volatility, IRWD or BCRX?

Do analysts prefer IRWD or BCRX?

Is IRWD or BCRX more profitable?

Does the media refer more to IRWD or BCRX?

Which has stronger earnings & valuation, IRWD or BCRX?

Summary

How does Ironwood Pharmaceuticals compare to Zenas BioPharma?

Do analysts recommend ZBIO or IRWD?

Which has more volatility and risk, ZBIO or IRWD?

Does the media prefer ZBIO or IRWD?

Is ZBIO or IRWD more profitable?

Which has higher earnings and valuation, ZBIO or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to Innoviva?

Do analysts recommend IRWD or INVA?

Does the media favor IRWD or INVA?

Do insiders and institutionals believe in IRWD or INVA?

Which has more volatility and risk, IRWD or INVA?

Which has preferable earnings & valuation, IRWD or INVA?

Is IRWD or INVA more profitable?

Summary

How does Ironwood Pharmaceuticals compare to Novavax?

Is IRWD or NVAX more profitable?

Do analysts recommend IRWD or NVAX?

Do insiders and institutionals believe in IRWD or NVAX?

Which has better earnings and valuation, IRWD or NVAX?

Does the media favor IRWD or NVAX?

Which has more risk and volatility, IRWD or NVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools